Dexcom shares plunge after cautious 2026 outlook, despite strong Q3 results, as analysts cite margin pressure and uncertainty around G7 sensor uptake and accuracy.
Microsoft signs massive AI deal with IREN, boosting its AI infrastructure and capacity.
Dexcom shares plunge after cautious 2026 outlook, despite strong Q3 results, as analysts cite margin pressure and uncertainty around G7 sensor uptake and accuracy.
Microsoft signs massive AI deal with IREN, boosting its AI infrastructure and capacity.